Patents Assigned to The Babraham Institute
-
Patent number: 9797014Abstract: The invention relates to a method of identifying VDJ recombination products which comprises the use of sequence specific enrichment and specific restriction endonuclease enzymes or other DNA-shearing approaches to provide high resolution and high throughput interrogation of antigen receptor repertoires.Type: GrantFiled: March 1, 2013Date of Patent: October 24, 2017Assignee: The Babraham InstituteInventors: Andrew Wood, Daniel Bolland, Louise Matheson, Anne Corcoran
-
Publication number: 20150031042Abstract: The invention relates to a method of identifying VDJ recombination products which comprises the use of sequence specific enrichment and specific restriction endonuclease enzymes or other DNA-shearing approaches to provide high resolution and high throughput interrogation of antigen receptor repertoires.Type: ApplicationFiled: March 1, 2013Publication date: January 29, 2015Applicant: The Babraham InstituteInventors: Andrew Wood, Daniel Bolland, Louise Matheson, Anne Corcoran
-
Publication number: 20140120136Abstract: The present invention provides novel methods of enhancing CD8+ T cell mediated immunity (also referred to as “CD8+ T cell immunity”) in a patient having a diseased state. In particular, the present invention provides for the enhanced expression of miR-155 in a population of patient specific T cells through the introduction of a nucleic acid molecule encoding a miR-155 transcript or a nucleic acid molecule encoding a chimeric antigen receptor and a miR-155 transcript into those cells, followed by the reintroduction of the T cells into the patient. The present invention also provides methods of enhancing the expansion of these T cells relative to control cells. Increased expansion of CD8+ T cells following enhanced miR-155 expression is directly related to enhanced CD8+ T cell immunity. The present invention further provides methods of enhancing anti-cancer immunity in a patient through the increased expression of miR-155 in patient specific T cells.Type: ApplicationFiled: October 11, 2013Publication date: May 1, 2014Applicants: The Babraham Institute, Philadelphia Health & Education Corporation d/b/a Drexel University College of MedicineInventors: Peter D. Katsikis, Donald T. Gracias, Martin Turner
-
Publication number: 20080274950Abstract: The potential role of so called ‘cell adhesion recognition motifs’ (CARs) in cadherin adhesion has been emphasized. Due to the importance of cadherin binding in biological process, there remains a need to develop effective ways of manipulating cadherin adhesion. According to the present invention, there is provided a pair of cadherin molecules modified to enhance intermolecular adhesion (i.e. adhesion or binding between the pair of cadherin molecules) compared with corresponding unmodified cadherin molecules. Intermolecular adhesion between the cadherin molecules may be enhanced by reducing or eliminating intramolecular binding within each cadherin molecule. For example, intramolecular binding may be reduced or eliminated by diminishing or preventing intramolecular binding of an N-terminal binding strand of each cadherin molecule with a binding strand acceptor pocket of each cadherin molecule.Type: ApplicationFiled: January 18, 2006Publication date: November 6, 2008Applicant: The Babraham InstituteInventors: Peter Kilshaw, Elaine Corps, Oliver Harrison
-
Publication number: 20060084790Abstract: A novel protein useful as an anti-inflammatory target is described. Methods of making the protein, and use of the protein in assays for identification of anti-inflammatory agents are described. Methods of making knock-out mice for the gene encoding the protein are also desired.Type: ApplicationFiled: March 21, 2003Publication date: April 20, 2006Applicant: The Babraham InstituteInventors: Len Stephens, Philip Hawkins
-
Patent number: 7029910Abstract: This invention relates to a control region in human immunoglobulins, to parts thereof and to their use.Type: GrantFiled: February 20, 2002Date of Patent: April 18, 2006Assignee: The Babraham InstituteInventors: Cornelia Anna Mundt, Marianne Brueggemann
-
Publication number: 20040231012Abstract: In humans, approximately 60% of expressed immunoglobulin light chains are of the Kappa type and 40% of the Lambda type. In mice, there is almost no expression from the Lambda locus and over 95% of light chains are of Kappa type. The present invention discloses, among other things, transgenic mice carrying most of the human Ig Lambda light chain locus in their genome. The resulting mice express light chains with Kappa/Lambda ratio similar to the human ratio. Breeding of HuIg Lamda mice to Kappa-deficient mice also is described, as well as the generation of human monoclonal antibodies from transgenic mice with human Ig Lambda locus.Type: ApplicationFiled: January 9, 2004Publication date: November 18, 2004Applicant: The Babraham InstituteInventor: Marianne Bruggemann
-
Patent number: 6348349Abstract: Embryonic stem cells or other cells (not prokaryotic or yeast) that are essentially free of yeast DNA are prepared from suitably marked yeast artificial chromosomes and used to transfer DNA segments of considerable size into organisms.Type: GrantFiled: July 6, 1998Date of Patent: February 19, 2002Assignee: The Babraham InstituteInventor: Marianne Bruggemann
-
Patent number: 6017763Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode the G protein regulated phosphatidylinositol-3' kinase, a heterodimeric enzyme which produces the intracellular messenger phosphatidylinositol (3,4,5)-triphosphate in response to activation of trimeric G protein-linked receptors. This novel protein, comprised of a catalytic subunit, p120, and a regulatory subunit, p101, is found in cells of hematopoietic origin and is involved in immune system responses which cause inflammation. The presence of p101 subunit is largely responsible for the dramatic stimulation of kinase activity in the presence of activated trimeric G proteins.Type: GrantFiled: January 4, 1999Date of Patent: January 25, 2000Assignees: Onyx Pharmaceuticals, Inc., The Babraham InstituteInventors: Len Stephens, Phillip Thomas Hawkins, Sylvia Braselmann
-
Patent number: 5776773Abstract: Embryonic stem cells that are essentially free of yeast DNA are prepared from suitably marked yeast artificial chromosomes and used to transfer DNA segments of considerable size into organisms.Type: GrantFiled: March 7, 1994Date of Patent: July 7, 1998Assignee: The Babraham InstituteInventor: Marianne Bruggemann
-
Patent number: 5545807Abstract: Chimaeric or wholly foreign immunoglobulin is obtained from cells or body fluid of a transgenic animal which has had inserted into its germline genetic material that encodes for at least part of an immunoglobulin, of foreign origin or that can rearrange to encode a repertoire of immunoglobulins, i.e. derived from a different animal source. For example, wholly human immunoglobulins may be produced from a transgenic mouse, possibly in response to an immunogen subsequently introduced to the mouse.Type: GrantFiled: August 5, 1994Date of Patent: August 13, 1996Assignees: The Babraham Institute, Medical Research CouncilInventors: Azim M. Surani, Michael S. Neuberger, Marianne Bruggemann